ReviewSensors (Basel, Switzerland)2021
COVID-19 Testing and Diagnostics: A Review of Commercialized Technologies for Cost, Convenience and Quality of Tests.
Review in Sensors (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 50 citations in OpenAlex.
- Article
- Scalable Alkaline Extraction Protocol for Microbial DNA Screening by PCR.Bio-protocol · 2025Article
- Smartphone-based device for point-of-care diagnostics of pulmonary inflammation using convolutional neural networks (CNNs).Scientific reports · 2024Article
- Advances in nanobiosensors during the COVID-19 pandemic and future perspectives for the post-COVID era.Nano convergence · 2024Review
- A decade of clinical microbiology: top 10 advances in 10 years: what every infection preventionist and antimicrobial steward should know.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2024Review
- Internationally standardized respiratory viral load testing with limited resources: A derivative-of-care calibration strategy for SARS-CoV-2.Influenza and other respiratory viruses · 2024Article
- Fast and Sustainable Thermo-osmotic DNA Extraction Protocol for Trans-spectrum Contingency and Field Use.Bio-protocol · 2023Article
- Physical distancing versus testing with self-isolation for controlling an emerging epidemic.Scientific reports · 2023Article
- Cycle Threshold (Ct) Values of SARS-CoV-2 Detected with the GeneXpertCurrent issues in molecular biology · 2023Article
- Multiplex sensing of IL-10 and CRP towards predicting critical illness in COVID-19 infections.Biosensors & bioelectronics: X · 2023Article
- Recent Advances in Molecular and Immunological Diagnostic Platform for Virus Detection: A Review.Biosensors · 2023Review
- Article
- The Use of Digital Technology for COVID-19 Detection and Response Management in Indonesia: Mixed Methods Study.Interactive journal of medical research · 2023Article
- Review
- Sniffing out safety: canine detection and identification of SARS-CoV-2 infection from armpit sweat.Frontiers in medicine · 2023Article
- Machine learning for the identification of respiratory viral attachment machinery from sequences data.PloS one · 2023Article
- Microfluidic detection of viruses for human health.Biomicrofluidics · 2022Article
- SARS-CoV-2 IgG Levels Allow Predicting the Optimal Time Span of Convalescent Plasma Donor Suitability.Diagnostics (Basel, Switzerland) · 2022Article
- Integrating Single Domain Antibodies into Field-Deployable Rapid Assays.Antibodies (Basel, Switzerland) · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Population-scale and rapid testing for SARS-CoV-2 continues to be a priority for several parts of the world. We revisit the in vitro technology platforms for COVID-19 testing and diagnostics-molecular tests and rapid antigen tests, serology or antibody tests, and tests for the management of COVID-19 patients. Within each category of tests, we review the commercialized testing platforms, their analyzing systems, specimen collection protocols, testing methodologies, supply chain logistics, and related attributes. Our discussion is essentially focused on test products that have been granted emergency use authorization by the FDA to detect and diagnose COVID-19 infections. Different strategies for scaled-up and faster screening are covered here, such as pooled testing, screening programs, and surveillance testing. The near-term challenges lie in detecting subtle infectivity profiles, mapping the transmission dynamics of new variants, lowering the cost for testing, training a large healthcare workforce, and providing test kits for the masses. Through this review, we try to understand the feasibility of universal access to COVID-19 testing and diagnostics in the near future while being cognizant of the implicit tradeoffs during the development and distribution cycles of new testing platforms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.